Earnings Call Intelligence Subscribe
Home › Call Sheets › SYK › Q4'25
Call sheet · Q4'25

Stryker (SYK)

Q4'25 earnings call · held 2026-01-29 · compared with the Q3'25 call · management-credibility review
11/12
Disclosure score
2 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is Mako's cash purchase inflection - hospitals switching from leases to outright buys signals both balance sheet strength and Stryker locking in years of recurring implant revenue from 3,000+ installed robots. While everyone focuses on the 11% Q4 growth beat, the real binding constraint is international product approval cycles (EU MDR delays) keeping global penetration artificially low compared to U.S. dominance. Lobo's most revealing quote: 'This is the first time we've had a change of the actual robot to a new robot since we bought Mako' yet the transition was flawless - showing platform durability others can't replicate. The systematic MedSurg sales force splitting strategy remains underappreciated as a sustainable growth engine. My view changes if international approvals accelerate faster than expected or if Mako utilization rates plateau in the U.S.

The 30-second version

  • The Mako Cash Conversion Story Nobody Saw Coming
  • MedSurg Becomes a $15B+ Growth Engine Through Sales Force Alchemy
  • Tariff Muscle Test Passed, But $400M Annual Hit Now Baked In

What changed this quarter

MetricQ3'25Q4'25Change
Organic Sales Growth9.5% (vs 11.5% prior year)11% Q4, 10.3% FY+150bps Q4 acceleration
Adjusted EPS$3.19 (+11.1% YoY)$4.47 (+11.5% YoY Q4), $13.63 FY (+11.8%)Sustained double-digit growth
Adjusted Operating Margin25.6% (+90bps YoY)30.2% Q4 (+100bps YoY)+460bps sequential expansion
U.S. Organic Growth10.6%11.2% FY+60bps sustained acceleration
MedSurg Organic Growth8.4%12.6%+420bps acceleration vs tough comp
Orthopedics Organic Growth11.4%8.4%-300bps deceleration on comps
Mako InstallationsBest ever Q3Record Q4 both U.S. and worldwideConsecutive record quarters
U.S. Knee Business8.4% organic7.6% organic-80bps but still market leading
Free Cash Flow ConversionNot specified81% of adjusted net earnings (vs 75% prior year)+600bps improvement
Cash from Operations$2.9B YTD$5B FY (+$820M YoY)+20% YoY growth

Accountability tracked

8 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full SYK Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.